Portuguese 
English 
Spanish 
3 min of reading 
0 comments 
Bayer Announces Global Job Cuts Amid Restructuring and Billion-Dollar Lawsuits Over Alleged Cancer Risk
According to information from FDR and official data from the company itself, the pharmaceutical industry giant Bayer confirmed on Wednesday (6) the layoff of approximately 12,000 employees worldwide. This measure is part of a global restructuring plan aimed at accelerating internal decisions and reducing administrative and managerial positions.
The German multinational, which ended June 2024 with around 90,000 employees, is facing one of the most delicate moments in its recent history. In addition to the pressure to improve efficiency and competitiveness, the company is also dealing with high-profile litigation involving the herbicide Roundup, accused of causing cancer in consumers and workers.
What Is Behind the Layoffs
According to Bayer’s statement, the decision to cut jobs is linked to the need to simplify its structure and make operations more agile. The goal is to eliminate layers of management that, according to the company, hinder quick responses to market changes.
-
SpaceX sets share price at $135 and targets a historic $75 billion IPO to debut on Nasdaq with a trillion-dollar market value
-
While the world rushes to mine lithium from Congo and Chile, Brazil sits on one of the largest reserves and has barely begun to explore.
-
Heir worked at thirteen in an ice cream factory without revealing he was the owner’s son; today, at twenty-five, he leads the best-selling ice cream brand for home consumption in the Northeast, grosses almost R$ 300 million, has 145 stores, and competes with multinationals with regional flavors.
-
Lock manufacturer from Rio Grande do Sul invests R$ 150 million to surpass R$ 1 billion in revenue, create 200 jobs, and double storage capacity, while choosing Santa Catarina to set up a new logistics center and speed up deliveries in Southern Brazil.
The reduction in the payroll occurs amid a backdrop of financial challenges, high competition, and pressure for results from investors. The move is also seen as part of a strategy to reposition Bayer in an increasingly demanding global environment.
The Roundup Case and the Weight of Lawsuits
The herbicide Roundup is at the epicenter of thousands of lawsuits in the United States. The product, widely used in agriculture, has been accused of causing cancer, resulting in damage to Bayer’s reputation and high legal costs.
To deal with potential indemnities, the company has already allocated US$ 7.4 billion and announced another 1.2 billion euros (about US$ 1.37 billion) for additional legal expenses. These amounts directly impact the financial health of the pharmaceutical giant, increasing the pressure for internal changes.
Pressure from Investors and Possible Structural Changes
The pharmaceutical industry giant is also facing pressure to sell part of its operations, including the consumer health division, or even to spin off its agricultural unit. Despite speculation, Bayer claims there are no concrete plans for divestiture or asset sales at this time.
Nevertheless, experts point out that the company needs to adopt efficiency measures and adapt to maintain relevance in the global market, considering the fierce competition and high legal costs it is facing.
A Future of Uncertainties
With over 150 years of activity, Bayer has built a solid reputation in the pharmaceutical and agricultural sectors, but is now facing a turbulent period. The success of the restructuring will depend on its ability to balance cost-cutting with investments in innovation and crisis management.
The combination of mass layoffs, billion-dollar lawsuits, and strategic changes places the company in a decisive moment — and the market will closely monitor every step taken.
And you, do you believe that the restructuring and the layoff of 12,000 employees will be enough to stabilize the pharmaceutical industry giant, or will the impact of the cancer accusations be irreversible? Leave your opinion in the comments — we want to hear from those who closely follow the sector.
Be the first to react!